CASI Pharmaceuticals Stock (NASDAQ:CASI)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$2.65

52W Range

$2.05 - $8.19

50D Avg

$4.82

200D Avg

$4.74

Market Cap

$35.92M

Avg Vol (3M)

$40.10K

Beta

0.65

Div Yield

-

CASI Company Profile


CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

176

IPO Date

Jun 12, 1996

Website

CASI Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 19
E V O M E L A$4.10M

Fiscal year ends in Dec 23 | Currency in USD

CASI Financial Summary


Dec 23Dec 22Dec 21
Revenue$33.88M$43.11M$30.17M
Operating Income$-31.65M$-26.49M$-35.28M
Net Income$-26.94M$-39.41M$-37.77M
EBITDA$-27.91M$-7.63M$-32.03M
Basic EPS$-2.02$-2.89$-2.78
Diluted EPS$-2.02$-2.89$-2.78

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 22Aug 12, 22 | 12:28 PM
Q1 22May 12, 22 | 11:32 AM
Q4 21Mar 28, 22 | 1:54 PM

Peer Comparison


TickerCompany
CDTXCidara Therapeutics, Inc.
CLRBCellectar Biosciences, Inc.